Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most medical/mechanism claims are partially supported by the label excerpts (indications and general TG/cardiovascular risk reduction). Several claims about discount programs are not addressable with the provided FDA prescribing information excerpts, and mechanism details (HDL increase) are contradicted or unsupported by the excerpts.
Category Scores
Accurate Statements
Vascepa is a prescription medication containing icosapent ethyl.
Drug identity/active ingredient: VASCEPA (icosapent ethyl) (Active ingredient: icosapent ethyl; dosage forms oral soft gelatin capsules).
Vascepa is used to treat high triglycerides.
Indication for severe hypertriglyceridemia: "as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia."
Vascepa is used to reduce the risk of cardiovascular events, such as heart attacks and strokes, in patients with high triglycerides and established cardiovascular disease.
Cardiovascular event risk reduction: "reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease".
Vascepa works by reducing the production of triglycerides in the liver.
Mechanism excerpt: "EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion".
Unsupported Statements
Vascepa works by increasing the levels of high-density lipoprotein (HDL) cholesterol.
No HDL-increase mechanism/effect is supported in the provided label excerpts; the excerpts discuss hepatic VLDL-TG synthesis/secretion, TG clearance, and TG reduction (and note reduction not associated with elevations in LDL-C).
Vascepa discounts require patients to be at least 18 years old.
The provided FDA prescribing information excerpts do not contain any details about discount program eligibility criteria (age, income, insurance, prescription limits, etc.).
Vascepa discounts require a certain income level to qualify, and the income level varies depending on the program and the patient's location.
Discount program eligibility criteria are not present in the provided FDA prescribing information excerpts.
Vascepa discounts require a patient to have insurance coverage for Vascepa.
Discount program eligibility/insurance requirements are not present in the provided FDA prescribing information excerpts.
Vascepa discounts require a medical condition that requires treatment with Vascepa, such as high triglycerides or cardiovascular disease.
The provided FDA prescribing information excerpts do not include eligibility requirements for discount programs.
The Vascepa Savings Card offers discounts of up to $50 per prescription for patients with commercial insurance.
Dollar amounts and card terms for discount programs are not present in the provided FDA prescribing information excerpts.
The Vascepa Patient Assistance Program provides free Vascepa to patients who are uninsured or underinsured.
Patient assistance program terms are not included in the provided FDA prescribing information excerpts.
Amarin, the manufacturer of Vascepa, offers coupons to reduce the cost of Vascepa.
Manufacturer coupon terms are not present in the provided FDA prescribing information excerpts.
Vascepa is eligible for discounts on up to 12 prescriptions per year.
Prescription limit eligibility for discount programs is not present in the provided FDA prescribing information excerpts.
Eligibility for Vascepa discounts may vary depending on the patient's insurance coverage and income level.
No discount program eligibility details are present in the provided FDA prescribing information excerpts.
Patients may be able to switch to a generic alternative to Vascepa to save money.
The provided FDA prescribing information excerpts do not address generic substitution or cost-saving alternatives.
Patients may be able to purchase Vascepa at a lower cost through mail-order pharmacies.
The provided FDA prescribing information excerpts do not address mail-order pharmacy availability or pricing.
Patients may be eligible for patient assistance programs that can provide free or discounted Vascepa.
While this is not a medical claim, patient assistance program availability/terms are not present in the provided FDA prescribing information excerpts.
Contradictions
Low
AI Statement
Vascepa works by increasing the levels of high-density lipoprotein (HDL) cholesterol.
Label Reference
Mechanism/effects excerpts do not state HDL increase; provided label excerpt notes TG/VLDL-C/Apo B reductions and that TG reduction was not associated with LDL-C elevations.
Important Omissions
In the cardiovascular-risk reduction claim, the label requires VASCEPA use as adjunct to maximally tolerated statin therapy and specifies adult populations with elevated TG (≥150 mg/dL) meeting additional criteria (established CVD or diabetes plus additional risk factors). The AI claim does not mention adjunct-to-statin or the diabetes/additional risk factor criterion.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The only potentially clinically misleading medical claim is the mechanism statement about increasing HDL, which is not supported by the provided label excerpts. Discount-program claims are unsupported by the label excerpts but are not directly tied to clinical safety. The cardiovascular indication claim is broadly consistent but omits 'adjunct to maximally tolerated statin therapy' and specified population details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
One mechanism claim (HDL increase) is not supported by the provided labeling excerpts, and multiple discount-program assertions are not supported because the FDA label excerpts provided do not contain those program details.
Suggested Improvement
Limit medical-mechanism statements to those supported in the provided label excerpts (e.g., hepatic VLDL-TG synthesis/secretion reduction and/or TG clearance). For cardiovascular risk reduction, include key label modifiers (adjunct to maximally tolerated statin therapy and adult elevated TG criteria with specified disease/risk-factor populations). Omit or qualify discount-program claims since they are not contained in the provided FDA prescribing information.